Effects of laughter therapy on quality of life in patients with cancer: An open-label, randomized controlled trial.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
12
2018
accepted:
12
06
2019
entrez:
28
6
2019
pubmed:
28
6
2019
medline:
25
2
2020
Statut:
epublish
Résumé
Few randomized controlled trials have assessed the effects of laughter therapy on health-related quality of life (QOL) in cancer patients. This study aimed to evaluate these effects as an exploratory endpoint in cancer patients as part of a randomized controlled trial conducted at a single institution in Japan. The Initiative On Smile And CAncer (iOSACA) study was an open-label randomized controlled trial conducted in 2017 in which participants aged 40-64 years with cancer were randomly assigned to either an intervention group (laughter therapy) or control group (no laughter therapy). Each participant in the intervention group underwent a laughter therapy session once every two weeks for seven weeks (total of four sessions). Each session involved a laughter yoga routine followed by Rakugo or Manzai traditional Japanese verbal comedy performances. We assessed QOL as a secondary endpoint in this intention-to-treat population using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The questionnaire was completed at baseline (Week 0) and at Weeks 3 and 7. Mixed-effects models for repeated measures were developed to compare time-dependent changes in each QOL domain from baseline between the intervention and control groups. Four participants retracted consent and one participant was retrospectively excluded from analysis due to unmet inclusion criteria. The analysis was conducted using 56 participants, with 26 in the intervention group and 30 in the control group. Questionnaire completion rates were high (>90%), with similar QOL scores reported at baseline in both groups. The mixed-effects models showed that the intervention group had significantly better cognitive function and less pain than the control group for a short period. Laughter therapy may represent a beneficial, noninvasive complementary intervention in the clinical setting. Further studies are needed to verify the hypotheses generated from this exploratory study.
Sections du résumé
BACKGROUND
Few randomized controlled trials have assessed the effects of laughter therapy on health-related quality of life (QOL) in cancer patients. This study aimed to evaluate these effects as an exploratory endpoint in cancer patients as part of a randomized controlled trial conducted at a single institution in Japan.
METHODS
The Initiative On Smile And CAncer (iOSACA) study was an open-label randomized controlled trial conducted in 2017 in which participants aged 40-64 years with cancer were randomly assigned to either an intervention group (laughter therapy) or control group (no laughter therapy). Each participant in the intervention group underwent a laughter therapy session once every two weeks for seven weeks (total of four sessions). Each session involved a laughter yoga routine followed by Rakugo or Manzai traditional Japanese verbal comedy performances. We assessed QOL as a secondary endpoint in this intention-to-treat population using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The questionnaire was completed at baseline (Week 0) and at Weeks 3 and 7. Mixed-effects models for repeated measures were developed to compare time-dependent changes in each QOL domain from baseline between the intervention and control groups.
RESULTS
Four participants retracted consent and one participant was retrospectively excluded from analysis due to unmet inclusion criteria. The analysis was conducted using 56 participants, with 26 in the intervention group and 30 in the control group. Questionnaire completion rates were high (>90%), with similar QOL scores reported at baseline in both groups. The mixed-effects models showed that the intervention group had significantly better cognitive function and less pain than the control group for a short period.
CONCLUSION
Laughter therapy may represent a beneficial, noninvasive complementary intervention in the clinical setting. Further studies are needed to verify the hypotheses generated from this exploratory study.
Identifiants
pubmed: 31247017
doi: 10.1371/journal.pone.0219065
pii: PONE-D-18-34050
pmc: PMC6597115
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0219065Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
J Rheumatol. 1996 Apr;23(4):793-4
pubmed: 8730156
Pediatrics. 2012 Mar;129(3):e762-70
pubmed: 22311995
Clin J Oncol Nurs. 2005 Apr;9(2):211-8
pubmed: 15853164
Int J Community Based Nurs Midwifery. 2015 Jan;3(1):31-8
pubmed: 25553332
J Altern Complement Med. 2015 Apr;21(4):217-22
pubmed: 25875938
CA Cancer J Clin. 2007 Sep-Oct;57(5):278-300
pubmed: 17855485
Control Clin Trials. 2002 Dec;23(6):662-74
pubmed: 12505244
Eur J Cancer. 1998 May;34(6):810-5
pubmed: 9797690
Pediatr Rev. 2008 Aug;29(8):e44-9
pubmed: 18676576
Int J Geriatr Psychiatry. 2007 Jan;22(1):77-83
pubmed: 16977676
Am J Med Sci. 1989 Dec;298(6):390-6
pubmed: 2556917
Iran J Cancer Prev. 2014 Fall;7(4):179-83
pubmed: 25628838
Onco Targets Ther. 2014 Nov 04;7:2053-9
pubmed: 25395864
Physiol Behav. 2006 Jul 30;88(4-5):303-8
pubmed: 16753190
Evid Based Complement Alternat Med. 2015;2015:864739
pubmed: 26064177
Front Psychol. 2018 Jun 19;9:890
pubmed: 29973892
J Pain Symptom Manage. 2000 Feb;19(2):91-9
pubmed: 10699536
Oncologist. 2005 Sep;10(8):651-60
pubmed: 16177290
Int J Geriatr Psychiatry. 2011 Mar;26(3):322-7
pubmed: 20848578
Lancet Oncol. 2016 Nov;17(11):1533-1542
pubmed: 27686943
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
N Engl J Med. 1976 Dec 23;295(26):1458-63
pubmed: 995143
J Clin Oncol. 2004 Jun 1;22(11):2233-9
pubmed: 15169812
BMJ. 2005 Apr 9;330(7495):843
pubmed: 15817555
Altern Ther Health Med. 2012 Sep-Oct;18(5):61-6
pubmed: 22894892
Pain. 1995 Nov;63(2):207-12
pubmed: 8628586
J Natl Cancer Inst. 1998 May 6;90(9):656-67
pubmed: 9586662
Altern Ther Health Med. 2003 Mar-Apr;9(2):38-45
pubmed: 12652882
Proc Biol Sci. 2012 Mar 22;279(1731):1161-7
pubmed: 21920973
Lancet Oncol. 2000 Nov;1:176-80
pubmed: 11905656
J Clin Oncol. 2002 Jul 15;20(14):3137-48
pubmed: 12118028
Eur J Cancer. 2010 Nov;46(16):2879-88
pubmed: 20605090
Geriatr Gerontol Int. 2013 Jan;13(1):152-60
pubmed: 22672359
J Cancer Educ. 2006 Spring;21(1):30-4
pubmed: 16918287
Cancer. 2010 Aug 15;116(16):3924-33
pubmed: 20626016
Ann Oncol. 2014 Jul;25(7):1428-36
pubmed: 24769640
Pain. 1998 Jun;76(3):365-75
pubmed: 9718255
BMC Complement Altern Med. 2010 Jun 18;10:28
pubmed: 20565815
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
J Cancer Surviv. 2009 Mar;3(1):43-58
pubmed: 19067178
Oncol Nurs Forum. 2002 Nov-Dec;29(10):1445-52
pubmed: 12432415
J Clin Oncol. 2011 Feb 20;29(6):755-60
pubmed: 21263086
Health Qual Life Outcomes. 2010 Jul 10;8:65
pubmed: 20618978